GHRP-2 Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What GHRP-2 Does & How It Works

What It Does , Functional Outcomes

• Triggers a pulse of growth hormone from the pituitary gland, mimicking the body's natural GH release pattern more closely than exogenous HGH
• Elevates IGF-1 over time, supporting lean muscle retention, fat metabolism, and tissue repair
• Accelerates recovery from training and soft tissue stress through GH and IGF-1 axis activity
• Improves sleep depth, particularly slow-wave sleep, which is where the majority of natural GH secretion occurs
• Stimulates appetite through ghrelin-mimetic peripheral signaling , a feature for some users, a drawback for others
• Moderately elevates cortisol and prolactin alongside GH , a distinguishing characteristic compared to more selective options
• Provides potential cardioprotective signaling through direct cardiac receptor engagement, based on preclinical evidence

How It Works , Mechanism of Action

GHS-R1a Receptor Activation and Pituitary GH Release (Evidence: Human)

GHRP-2 binds to GHS-R1a , the ghrelin receptor expressed on somatotroph cells (the specialized growth hormone-producing cells in the anterior pituitary gland). This binding directly stimulates those cells to release growth hormone in a discrete pulse. GHS-R1a is also expressed throughout the hypothalamus and in numerous peripheral tissues, which is why GHRP-2 produces effects beyond the pituitary alone. The receptor activation mimics the action of endogenous ghrelin , the body's natural GHS-R1a ligand , with approximately 2-3 times the potency of GHRP-6 on a molar basis for GH secretion.

Somatostatin Suppression and Synergistic Amplification (Evidence: Animal and In vitro)

Simultaneously with its pituitary action, GHRP-2 acts at the hypothalamic level to suppress somatostatin , the peptide that normally acts as the brake on GH secretion. Removing that inhibitory signal while activating the pituitary amplifies the GH response beyond what pituitary stimulation alone produces. This dual action is why GHRP-2 combined with a GHRH analog produces substantially greater GH output than either compound alone. The GHRH analog directly stimulates the pituitary through a separate receptor while GHRP-2 simultaneously removes the brake and activates through GHS-R1a.

IGF-1 Axis Downstream Effects (Evidence: Animal and limited human)

The GH released by GHRP-2 stimulation travels to the liver, where it signals hepatocytes (liver cells) to produce Insulin-Like Growth Factor-1 (IGF-1). IGF-1 mediates many of the downstream anabolic and regenerative effects attributed to GH axis stimulation , including muscle protein synthesis support, fat oxidation, and tissue repair signaling. Chronic GHRP-2 administration has been shown to elevate serum IGF-1 levels in both animal and human studies with repeated dosing. This suggests the GH pulses are translating into meaningful downstream axis activity.

Cortisol and Prolactin Co-Secretion (Evidence: Human)

GHRP-2 produces dose-dependent elevation of cortisol and prolactin alongside GH , a pharmacological characteristic confirmed in multiple human endocrine studies. This co-secretion is notably more pronounced than what is observed with Ipamorelin, which was designed specifically for high GHS-R1a selectivity. The cortisol and prolactin elevations are transient, resolving as the GH pulse subsides. They are consistent across users and are a central consideration when comparing GHRP-2 to more selective alternatives.

Anti-Apoptotic Cardioprotective Signaling (Evidence: Animal , rat and pig models)

Beyond its pituitary effects, GHRP-2 engages CD36 receptors , protein receptors found on the surface of cardiac muscle cells , and activates the PI3K/Akt pathway (a cell-survival signaling cascade that tells stressed cells to stay alive rather than self-destruct) in cardiomyocytes (heart muscle cells). This signaling reduces programmed cell death in cardiac tissue under oxygen deprivation , the mechanism behind the cardioprotective findings in myocardial ischemia research. This appears to operate as a direct cardiac action that does not require GH release as an intermediary. That finding suggests GHRP-2 has meaningful biology at cardiac tissue that is distinct from its pituitary effects.

GHRP-2 Molecular Profile

Structure reference: View GHRP-2 on PubChem , Publishing team: retrieve 2D structure image from this link.

GHRP-2 Uses & Benefits

GH Axis Stimulation and Anti-Aging

GHRP-2 is most broadly used for what is often called GH optimization , stimulating the pituitary to produce more growth hormone in individuals whose natural GH output has declined with age. Age-related decline in GH secretion (somatopause) begins in the third decade and accelerates thereafter, contributing to changes in body composition, recovery capacity, and metabolic function. GHRP-2 addresses this by driving GH pulses through the body's own pituitary rather than replacing GH exogenously, preserving the natural pulsatile secretion pattern that exogenous HGH bypasses. Evidence for sustained IGF-1 elevation with repeated dosing supports the idea that these pulses translate into meaningful downstream axis activity. (Evidence: Moderate , animal consistent; human data limited to short-duration trials)

Body Composition , Lean Mass and Fat Loss

The body composition application of GHRP-2 follows directly from GH and IGF-1 axis stimulation. GH promotes lipolysis (the breakdown of stored fat into usable energy) and IGF-1 supports muscle protein synthesis, so sustained GH axis activity over weeks to months is expected to shift the muscle-to-fat ratio. Short-term human trials and more extensive animal model research document modest but consistent improvements in lean body mass and reductions in fat mass with chronic GHRP-2 administration. The effects are generally described as less dramatic than exogenous HGH but more physiological in their pattern , appropriate for long-term body composition management rather than rapid transformation. (Evidence: Moderate , animal consistent; human data small-sample)

Recovery and Tissue Repair

GH and IGF-1 stimulation supports collagen synthesis, connective tissue repair, and the cellular regenerative processes relevant to recovery from training and injury. GHRP-2's role in tissue repair is indirect , working through GH and IGF-1 elevation rather than direct tissue-level action , which distinguishes it from compounds like BPC-157 that operate through local regenerative mechanisms. Users in tracked protocols frequently cite improved recovery from training and from soft tissue stress as a primary benefit. Animal model data supports wound healing and connective tissue repair effects through GH axis upregulation. (Evidence: Moderate , animal; limited human)

Sleep Quality

Growth hormone is predominantly secreted during slow-wave sleep, and this relationship runs in both directions , the GH pulse and slow-wave sleep amplitude mutually reinforce each other. Administering GHRP-2 before sleep is documented in tracked protocols as producing noticeably improved sleep depth, which users attribute to the amplified GH pulse during the nocturnal secretion window. Formal human sleep study data for GHRP-2 is limited, but the biological mechanism connecting GH pulsatility and slow-wave sleep architecture is well-established. The pre-sleep administration window is consistently recommended across functional medicine practitioners who work with GHS peptides. (Evidence: Preliminary , mechanistic basis strong; formal human sleep data limited)

Growth Hormone Deficiency Diagnosis (Clinical)

In Japan, GHRP-2 is approved under the name Pralmorelin as a diagnostic provocative agent for GHD assessment. A single supervised intravenous dose stimulates the pituitary, and peak GH output measured from serial blood draws indicates whether the gland has adequate secretory capacity. This is the one application where GHRP-2 has cleared formal regulatory review, and the Japanese clinical literature provides the highest-quality human evidence for the compound's GH-stimulating activity. Outside Japan, this diagnostic application remains investigational. (Evidence: Strong , approved clinical indication in Japan)

Appetite Stimulation

GHRP-2's peripheral ghrelin-mimetic action stimulates appetite , a predictable consequence of GHS-R1a activation in gut and hypothalamic tissues. The appetite-stimulating effect is moderate compared to GHRP-6 (which produces substantially stronger hunger) and more pronounced than Ipamorelin (which produces minimal appetite stimulation). For users in building phases or dealing with low appetite, this effect is a feature. For users managing caloric intake for fat loss, it can be counterproductive and is one reason Ipamorelin is sometimes chosen instead. (Evidence: Moderate , documented in human and animal studies)

Where This GHRP-2 Guide Comes From

GHRP-2 Results & Timelines

GH Axis Stimulation , Acute and Cumulative Effects

• Within 15-30 minutes of first injection: Measurable GH pulse , this is one of the fastest-acting effects of any GHS peptide and is confirmed in human studies
• Days 3-7: Changes in appetite and sleep depth are commonly the first subjective signals; some users report improved sleep quality and more vivid dreams within the first week
• Week 2-4: Mild water retention may become noticeable; energy and recovery from training sessions commonly reported as improved during this window
• Week 6-12: Cumulative IGF-1 elevation and its downstream effects , improved body composition, connective tissue support, continued recovery benefits , become more apparent with consistent use
• Month 3-6: The range most commonly documented for meaningful body composition and anti-aging outcomes in tracked protocols; results that are observable and measurable rather than subtle typically emerge in this timeframe

Sleep Quality

• Week 1-2: Pre-sleep dosing is among the earliest applications where users report noticeable subjective change , deeper sleep and improved morning recovery within the first 1-2 weeks is commonly reported
• Week 4+: Sustained improvement; some users report that consistent pre-sleep dosing becomes one of the most valued aspects of a GHRP-2 protocol independent of body composition goals

Body Composition

• Week 1-4: Little to no visible body composition change expected; the GH and IGF-1 axis needs sustained stimulation before meaningful shifts in lean mass or fat distribution become apparent
• Week 6-12: Initial body composition shifts , modest reductions in fat and modest support for lean tissue , become measurable in tracked protocols
• Month 3-6: Most documented protocols show the clearest body composition results in this range, consistent with the timeline required for GH and IGF-1 axis adaptation

Recovery and Tissue Repair

• Week 2-4: Improved workout-to-workout recovery is frequently reported early in GHRP-2 protocols; training volume tolerance may increase
• Week 6-12: Connective tissue support and soft tissue recovery benefits become more apparent with sustained GH and IGF-1 elevation

How to Administer GHRP-2

Subcutaneous Injection (SubQ)

Subcutaneous injection is the standard route for investigational GHRP-2 use and is the method used in the majority of documented research protocols. The peptide is injected into the subcutaneous fat layer , typically the abdomen, outer thigh, or upper arm. Subcutaneous bioavailability is estimated at approximately 70-90% relative to intravenous administration, and the GH pulse it produces is rapid and predictable. Most tracking data for dose-response, timing, and outcome timelines is based on SubQ administration.

Intramuscular Injection (IM)

Intramuscular injection is technically feasible for GHRP-2 but is not the standard route in documented investigational protocols. The bioavailability difference between IM and SubQ for this compound is not well-characterized, and SubQ is preferred for its practical simplicity and the established pharmacokinetic data. IM is not routinely recommended in tracked protocols for GHRP-2.

Nasal / Intranasal

Intranasal GHRP-2 administration is documented and available from some specialty compounders. Bioavailability via the intranasal route is substantially lower than injectable , estimated at approximately 5-10% of the intravenous reference standard. This means a nasal dose must be meaningfully larger than an injectable dose to produce a comparable GH response, and the consistency of absorption is less predictable. Some users who prefer to avoid injections use the intranasal route despite these limitations; the GH response is real but reduced compared to SubQ.

Oral

Oral administration of GHRP-2 produces negligible bioavailability , estimated below 1%. The peptide bonds in GHRP-2 are cleaved by digestive enzymes in the stomach and small intestine before the compound reaches systemic circulation in active form. While the D-amino acid modifications in GHRP-2's structure confer some resistance to enzymatic degradation that extends its plasma half-life compared to simpler peptides, that resistance is insufficient to survive the GI tract intact in meaningful quantities. Oral administration is not a viable route for GHRP-2.

GHRP-2 Dosage & Cycle Length

Overall dosing range: 100-300 mcg per injection, typically 2-3 times daily , range varies by goal and individual

How the goal shifts where you land:

• Low end of range (100 mcg per injection): Most commonly documented in published research and diagnostic protocols; associated with meaningful GH stimulation with the least cortisol and prolactin co-release; appropriate for general GH axis support, sleep quality, and conservative anti-aging applications
• Mid range (150-200 mcg per injection): The range most frequently reported in tracked investigational protocols for body composition and recovery goals; balances GH response amplitude against the cortisol and prolactin side effects that increase with dose
• High end of range (250-300 mcg per injection): Used in more aggressive body composition and recovery protocols; evidence suggests GH stimulation plateaus above mid-range doses, so pushing higher yields diminishing returns on GH while cortisol and prolactin effects continue to climb (evidence grade: Animal and limited human)

Frequency: Typically 2-3 times per day in investigational protocols. Timing is a meaningful variable. Administering GHRP-2 in a fasted state , at least 30-60 minutes before eating, or at least two hours after a carbohydrate- or fat-containing meal , significantly improves the GH pulse amplitude. Common dosing windows are upon waking in a fasted state and approximately 30-60 minutes before a workout. The pre-sleep window is also commonly used, as it aligns GHRP-2's GH pulse with the body's natural nocturnal GH secretion. That nocturnal secretion occurs primarily during slow-wave sleep.

Cycle length: Typically 3-6 months in documented investigational protocols. Some protocols incorporate a break period of 4-6 weeks after a 3-month run, on the theoretical basis that receptor desensitization may reduce efficacy over very long continuous use. The evidence for clinically significant GHS-R1a desensitization with GHRP-2 specifically is mixed, and some tracked data suggests maintained efficacy over extended periods without cycling.

Combination dosing context: When GHRP-2 is used alongside a GHRH analog such as CJC-1295 or Sermorelin, both are typically administered at the same time , the synergistic GH release requires simultaneous activation of both receptor pathways. The rationale is educational: these two compound classes act through separate but complementary mechanisms, and the combination effect is documented to be substantially larger than either alone. Specific stack protocols and how they interact with your individual health profile are best built with a personalized tool rather than a generic starting point.

GHRP-2 Vial Sizes, Costs & Quality

Common vial sizes: 2 mg, 5 mg, and 10 mg vials are all available from research peptide suppliers; 5 mg is the most commonly encountered size in the current market

Typical cost range: $40-$90 per vial for U.S.-manufactured research-grade GHRP-2 at current market pricing , varies by supplier, vial size, and documented purity level. Smaller 2 mg vials tend toward the lower end of that range; 5 mg and 10 mg vials from suppliers with third-party testing and certificates of analysis trend toward the higher end.

Storage , lyophilized (dry powder):

• Temperature: Long-term storage at -20 degrees C (freezer) is recommended; shorter-term storage of weeks to a few months at 2-8 degrees C (refrigerated) is generally acceptable
• Shelf life: Lyophilized GHRP-2 is stable for 12-24 months under proper freezer conditions; stability degrades meaningfully at room temperature over time
• Light sensitivity: Protect from light; store in original vial in a dark location or wrapped in foil

Storage , reconstituted (in solution):

• Temperature: Refrigerate at 2-8 degrees C immediately after reconstitution; do not freeze the reconstituted solution
• Use window: Typically within 28-30 days of reconstitution under refrigerated conditions; discard if outside this window

Normal appearance after reconstitution: GHRP-2 dissolves into a clear, colorless solution. A fully dissolved vial should show no visible particles, cloudiness, or color. Some very slight turbidity during mixing that clears as the peptide fully dissolves is normal , persistent cloudiness after thorough mixing is not.

Signs of degradation: Visible cloudiness or particulates that do not resolve, any discoloration (yellowish or brownish tint), or an unusual odor are indicators of degradation or contamination. Degraded peptide should not be used.

Quality Considerations

GHRP-2 synthesis quality varies more than most buyers realize. It matters here because the cortisol and prolactin co-release this peptide produces is dose-sensitive. A vial containing less active peptide than claimed will underperform. A vial that is more concentrated than labeled creates unpredictable dosing and elevated side effect risk.

Synthesis shortcuts typically show up as incomplete purification , meaning the vial contains GHRP-2 alongside synthesis byproducts that should have been removed. There is no way to detect this without a certificate of analysis from a verified third-party lab using HPLC (high-performance liquid chromatography, the standard method for confirming peptide purity) alongside mass spectrometry to confirm molecular weight.

Most budget-priced products online come from overseas facilities. Purification standards, sterility testing, and molecular weight verification are not independently confirmed at those sources. U.S.-manufactured research peptides cost more. The manufacturing process , synthesis, purification, purity verification, endotoxin testing , is done properly and documented. For a compound that is injected and whose side effect profile is genuinely dose-dependent, that documentation matters.

GHRP-2 Side Effects & Safety

Side Effect Spectrum

Contraindications

• Active malignancy: GH and IGF-1 elevation can theoretically stimulate growth of existing tumors through IGF-1 receptor signaling. This is a standard contraindication across all GHS compounds and exogenous GH. Insufficient data exist to characterize the actual risk magnitude in humans, but the theoretical basis is well-established.
• Pituitary tumor or adenoma: GHRP-2 stimulates the pituitary gland directly. Use in individuals with known pituitary pathology is not appropriate without specialist medical supervision.
• Uncontrolled diabetes: GH exerts counter-regulatory effects on insulin , it promotes insulin resistance, which can complicate blood glucose management. Use requires careful monitoring and should not be undertaken without medical oversight.
• Known hypersensitivity to any component: Standard peptide contraindication

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: No safety data exists for GHRP-2 in pregnancy or lactation; use is not recommended without direct medical supervision
• Pediatric use: Not studied in pediatric populations. GH axis stimulation in children carries specific risks including potential disruption of natural GH pulsatility and concerns about premature epiphyseal closure. Not appropriate without specialist pediatric endocrinology supervision.
• Individuals with pre-existing cardiovascular disease: While preclinical data suggests potential cardioprotective effects, clinical evidence is insufficient to characterize risk vs. benefit; medical supervision is warranted
• Individuals with elevated cortisol or HPA axis dysregulation: The HPA axis (hypothalamic-pituitary-adrenal axis) is the hormonal chain that governs your body's cortisol stress response. GHRP-2's cortisol co-stimulation may be counterproductive in individuals already dealing with stress-related hormonal imbalance.
• Individuals prone to water retention or with cardiovascular conditions affecting fluid status: GH-mediated water retention may be more pronounced or clinically relevant in these populations

Red Flags , Stop Use and Seek Medical Attention If:

• Significant swelling, particularly in the hands and feet, that does not resolve within a few days
• Chest pain, palpitations, or any cardiovascular symptoms following administration
• Severe or persistent headache disproportionate to any prior experience
• Signs of hypoglycemia , dizziness, confusion, cold sweats, shakiness , especially in individuals using insulin or other blood glucose-affecting agents
• Any unusual neurological symptoms including vision changes or significant numbness beyond the mild tingling that is commonly reported

Drug and Compound Interactions

Several documented and theoretical interactions are worth noting. Somatostatin analogs such as octreotide or lanreotide would directly antagonize GHRP-2's GH-releasing mechanism and essentially block its effects. Glucocorticoid medications may blunt the GH response. Insulin and antidiabetic agents require careful monitoring because GH exerts counter-regulatory effects on insulin sensitivity , individuals managing blood glucose with medication need to account for this interaction. Sex hormones, particularly estrogen, influence GH secretion patterns and may affect GHRP-2 responsiveness. No formal drug interaction studies specific to GHRP-2 investigational use have been conducted; the interaction data above is extrapolated from GH physiology and the pharmacology of the drugs involved.

GHRP-2 Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability

Subcutaneous GHRP-2 is absorbed rapidly, with bioavailability estimated at approximately 70-90% relative to the intravenous reference. Peak plasma concentrations arrive quickly following SubQ administration. The resulting GH pulse is measurable within 15-30 minutes. Intranasal bioavailability is substantially lower, estimated at 5-10% of the injectable route. Oral bioavailability, where data is available, indicates near-complete degradation , below 1%.

Distribution

GHRP-2 is distributed to both central and peripheral tissues. It crosses the blood-brain barrier (the protective filter that controls which substances can pass from the bloodstream into brain tissue) to a meaningful extent , hypothalamic GHS-R1a engagement is part of its documented mechanism. GHS-R1a expression in cardiac tissue is the basis for the cardioprotection research. Note that pharmacokinetic distribution data for GHRP-2 in humans is limited; most detailed distribution data comes from animal models.

Half-Life

Plasma half-life is approximately 15-60 minutes following injection. This relatively short duration is why the compound produces discrete GH pulses rather than sustained elevation. The D-amino acid substitutions at positions 1, 2, and 5 of the hexapeptide sequence confer resistance to enzymatic degradation. This resistance extends the half-life beyond what an equivalent all-L-amino acid peptide would achieve. Even so, the half-life remains short in absolute terms, which is why multiple daily administrations are typical.

Metabolism & Elimination

GHRP-2 is metabolized primarily by peptidases , enzymes that circulate in blood and are present in various tissues, whose job is to break peptides apart. Renal excretion of peptide fragments and metabolites follows. No significant accumulation is documented at standard dosing intervals.

Data gap note: Detailed human pharmacokinetic data for GHRP-2 in subcutaneous investigational use is limited. The half-life and bioavailability figures cited reflect data from the diagnostic clinical literature and animal pharmacokinetic studies rather than a robust human PK dataset.

Mechanistic Research

GHS-R1a Receptor Binding and GH Secretion (Evidence: Human , clinical diagnostic data)

GHRP-2 was among the compounds used to elucidate the GHS-R1a receptor pathway before the receptor was fully characterized. The GH secretagogue receptor itself was named in part based on work with GHRP-2 and related compounds. Human clinical studies evaluating GHRP-2 as a diagnostic agent directly confirmed GHS-R1a-mediated GH release in healthy adults and in individuals with GHD. In diagnostic studies, intravenous GHRP-2 produced robust, multi-fold increases in serum GH above baseline in healthy adults, with peak levels at approximately 30-60 minutes post-administration.

Somatostatin Suppression and Synergistic GH Amplification (Evidence: Animal and In vitro)

Studies in animal models confirmed GHRP-2's hypothalamic action , specifically, reduction in somatostatin release that removes the physiological brake on GH secretion. Combination studies in animal models and healthy human volunteers demonstrated that GHRP-2 co-administered with GHRH produces GH responses substantially exceeding either compound alone. This validated the dual-pathway synergy model. The magnitude of potentiation reported in various combination studies ranges from approximately 2-fold to over 10-fold compared to either compound individually, depending on the specific GHRH analog, dose, and model used.

Cortisol and Prolactin Co-Secretion (Evidence: Human)

Multiple human studies evaluating GHRP-2's endocrine effects confirmed dose-dependent elevation of both cortisol and prolactin alongside GH. This co-secretion was consistently observed across studies and is now well-characterized as a distinguishing feature of GHRP-2 compared to more selective GHS compounds. The clinical significance of short-term cortisol and prolactin elevation at standard doses is generally considered minor in healthy adults. However, this finding is why GHRP-2 is distinguished from Ipamorelin in clinical comparisons of GHS selectivity.

Anti-Apoptotic and Cardioprotective Signaling (Evidence: Animal , rat and pig models)

A substantive body of preclinical research in rat and pig myocardial ischemia models demonstrated that GHRP-2 reduces infarct size and cardiomyocyte (heart muscle cell) death when given before or during ischemic events. The primary mechanism involves activation of the PI3K/Akt pathway , a cell-survival signaling cascade. This cascade tells oxygen-deprived cardiac cells to resist programmed self-destruction. CD36 receptor engagement in cardiac cells appears to contribute independently of GHS-R1a, suggesting a direct cardiac action that does not require GH as an intermediary.

Condition-Focused Research

Growth Hormone Deficiency Diagnosis {#research-ghd}

The Pralmorelin stimulation test uses a single IV bolus of GHRP-2 followed by serial GH measurements. It was evaluated in multiple Japanese clinical studies comparing its diagnostic performance to established provocative tests for GHD. Studies found the Pralmorelin test had sensitivity and specificity for GHD detection comparable to or better than arginine and clonidine stimulation tests. It also carried a substantially lower risk profile than the insulin tolerance test, which requires inducing hypoglycemia. A peak GH threshold is used as the normal response cutoff to distinguish adequate pituitary secretory capacity from deficiency. These studies formed the basis for Japan's regulatory approval of Pralmorelin as a diagnostic agent. (Evidence: Human clinical , approved indication)

Body Composition and Aging {#research-body-comp}

Short-term human trials evaluating GHRP-2 in aging populations with age-related GH decline reported modest improvements in lean body mass and reductions in fat mass. These findings are consistent with the expected physiological effects of GH and IGF-1 axis stimulation. Studies were typically small in sample size and short in duration, limiting the strength of conclusions that can be drawn. Animal models using chronic GHRP-2 administration showed more consistent and pronounced body composition effects, providing mechanistic support for the human observations. IGF-1 elevation was confirmed in both human and animal studies with repeated dosing. (Evidence: Moderate , animal data consistent; human data small-sample, short-duration)

Cardioprotection {#research-cardio}

Preclinical research in rat models of myocardial infarction consistently demonstrated that GHRP-2 reduced the area of damaged cardiac tissue when administered around the time of ischemic insult. Pig model studies extended these findings and helped characterize the CD36 and PI3K/Akt mechanisms involved. The preclinical evidence base for cardioprotection is relatively robust for an investigational peptide , multiple independent research groups have replicated aspects of this finding. However, no controlled human data translating this into clinical cardioprotection currently exists. The optimal timing, dose, and route for any hypothetical cardioprotective application in humans remains undefined. (Evidence: Moderate preclinical; no human data)

NAFLD and Metabolic Health {#research-metabolic}

Emerging preclinical research has examined GHRP-2's potential effects on hepatic (liver) fat accumulation and metabolic dysfunction. The GH and IGF-1 axis is well-established as a regulator of hepatic lipid metabolism , GH deficiency is associated with increased hepatic fat. GHRP-2's ability to stimulate this axis provides a theoretical basis for investigating its role in conditions like non-alcoholic fatty liver disease. Animal model research exploring this application is ongoing but early; human data is absent. (Evidence: Preliminary , preclinical only)

Safety & Tolerability Research

Safety data for GHRP-2 in human subjects is most robust from the diagnostic use context , the single IV bolus Pralmorelin test. In these controlled clinical settings, GHRP-2 was generally well-tolerated with no serious adverse events reported in the diagnostic literature. The cortisol and prolactin elevations documented in human endocrine studies are transient and dose-dependent, resolving as the GH pulse subsides. Long-term safety data for repeated subcutaneous administration in investigational protocols is a significant gap in the evidence base , the controlled studies conducted to date were short-duration. The long-term implications of repeated cortisol and prolactin co-stimulation have not been formally characterized in human subjects. No formal toxicology or carcinogenicity studies in humans are available for GHRP-2 in the repeated-dose investigational context.

Research Limitations

GHRP-2's research base has a structural limitation that shapes the entire evidence picture: the highest-quality human data comes from single-dose diagnostic studies, not from the repeated subcutaneous dosing that characterizes investigational use. Body composition, recovery, and anti-aging applications , which account for most real-world use , are supported primarily by animal data and small, short-duration human trials rather than large controlled studies. No long-term safety data from repeated human dosing exists in the published literature. The cortisol and prolactin co-secretion findings are confirmed in humans, but their clinical implications over months of use have not been systematically studied. Human data on cardioprotection applications , despite compelling preclinical evidence , is essentially absent. Optimal dosing ranges for specific therapeutic targets have not been established in human trials for any application outside diagnostic use.

Is GHRP-2 Legal? Regulatory & Sports Status

FDA status: GHRP-2 is not approved for any therapeutic or diagnostic indication in the United States. It is not a scheduled controlled substance under the DEA's Controlled Substances Act. In research and commercial contexts it is classified as a research chemical. The FDA has taken enforcement actions against compounding pharmacies producing growth hormone secretagogue peptides, and GHRP-2 is among the compounds subject to these restrictions. Marketing or selling GHRP-2 for human consumption in the United States is not permitted; it is available from research peptide suppliers with "research use only" labeling.

Approved indication (Japan): GHRP-2 holds regulatory approval in Japan under the name Pralmorelin, marketed by Kaken Pharmaceutical, specifically as a diagnostic agent for growth hormone deficiency testing. This approval covers a single intravenous dose in a supervised clinical setting , it is not an approval for ongoing therapeutic use.

Research Use Only (RUO): In most countries, GHRP-2 is classified as a research compound and is not approved for human therapeutic use. Buyers and users are responsible for understanding the applicable laws in their specific jurisdiction, which vary meaningfully across countries.

WADA / USADA status: GHRP-2 is explicitly named on the WADA Prohibited List under category S2 , Peptide Hormones, Growth Factors, Related Substances and Mimetics. It is prohibited both in-competition and out-of-competition. Any athlete subject to anti-doping regulations , including USADA jurisdiction for U.S.-based athletes , must avoid GHRP-2. This is not a borderline or ambiguous classification; GHRP-2 is specifically listed as a prohibited growth hormone secretagogue.

Country-specific notes: In Australia, GHRP-2 is classified as a Schedule 4 Prescription Only Medicine and cannot be legally imported without a valid prescription; ASADA prohibits its use by Australian athletes. In the European Union, GHRP-2 is not approved; it falls under research chemical status. In the United Kingdom, it is not specifically scheduled as a controlled substance but cannot be sold for human use without regulatory approval. In Canada, the regulatory framework is similar to the United States , unapproved for human use.

Detection: Detection methods for GHRP-2 in both urine and blood samples have been developed and are used in anti-doping testing. The detection window varies by test type and dose but is generally short given GHRP-2's rapid plasma clearance , the GH elevation it produces may be detectable for longer than the peptide itself.

GHRP-2 vs. Alternatives

Commonly Paired With , Synergistic Stacks

• GHRP-2 + CJC-1295 (with DAC): The most widely used GHRP-2 combination in tracked protocols. CJC-1295 with DAC is a long-acting GHRH analog that provides sustained GHRH receptor stimulation over several days, while GHRP-2 adds acute pulsatile GHS-R1a stimulation and somatostatin suppression on top of that baseline. The two pathways converge to produce substantially greater GH output than either compound alone, and the combination is often used for body composition and anti-aging protocols where maximizing the GH stimulus is the primary objective.
• GHRP-2 + Modified GRF 1-29 (CJC-1295 No DAC): Similar rationale to the above but with a shorter-acting GHRH analog co-dosed at the same time as GHRP-2, producing a sharper, more pulsatile combined GH spike rather than a sustained baseline elevation. Users who prefer a more natural pulsatile GH pattern , particularly for pre-sleep dosing , often favor this combination over the long-acting DAC version.
• GHRP-2 + Sermorelin: Sermorelin is an older, shorter-acting GHRH analog. The synergistic combination rationale is identical to the other GHRH pairings, though Sermorelin's shorter half-life means the combined effect is more transient. This combination appears in functional medicine and anti-aging clinic protocols with some frequency, particularly where prescribing access to Sermorelin exists.
• Stacking information is for educational context , individualized stack protocols live inside MPP.

Alternatives , When Another Peptide May Be Considered

Ipamorelin Ipamorelin is a GHS peptide that operates through the same GHS-R1a receptor as GHRP-2 but with significantly greater selectivity , it produces GH release with minimal cortisol or prolactin co-stimulation. Users who find GHRP-2's cortisol and prolactin elevations problematic, or who prioritize a cleaner side effect profile, frequently choose Ipamorelin instead. The tradeoff is that GHRP-2 is generally considered more potent for GH release at equivalent doses, meaning Ipamorelin's cleaner profile comes at some cost to amplitude of effect.

GHRP-6 GHRP-6 is the predecessor to GHRP-2 , similar mechanism, older compound, somewhat less potent for GH release. The primary practical difference is that GHRP-6 produces substantially stronger appetite stimulation than GHRP-2 through its more pronounced peripheral ghrelin-mimetic effects. Users in bulking or weight-gain phases who want appetite stimulation as a feature sometimes choose GHRP-6 for that reason; users managing body composition who find hunger stimulation counterproductive typically prefer GHRP-2 or Ipamorelin.

Hexarelin Hexarelin is considered more potent than GHRP-2 for GH release but is associated with faster receptor desensitization with repeated use , meaning efficacy may decline more quickly over a cycle. It also produces more pronounced cardiovascular effects and cortisol elevation than GHRP-2. Hexarelin tends to appear in shorter, more intensive protocols where maximum GH stimulation over a limited duration is the goal rather than sustained long-term use.

MK-677 (Ibutamoren) MK-677 is an oral, non-peptide GHS mimetic that activates the same GHS-R1a receptor as GHRP-2. Its primary practical advantage is oral bioavailability , no injections required , and a near-24-hour half-life that produces sustained GH and IGF-1 elevation without multiple daily administrations. The tradeoffs include stronger and more persistent appetite stimulation, more pronounced water retention, and a less pulsatile GH release pattern. Users who cannot or will not inject often compare MK-677 to GHRP-2 directly; the two are not interchangeable but serve overlapping goals through different delivery mechanisms.

Comparison table:

Build Your GHRP-2 Protocol

FAQs

What is GHRP-2?

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide , a chain of six amino acids , that stimulates the pituitary gland to release growth hormone by activating the ghrelin receptor (GHS-R1a). It was developed in the 1980s and 1990s as a more potent successor to GHRP-6, and it is the only growth hormone secretagogue peptide to have received regulatory approval anywhere in the world, specifically in Japan for diagnosing growth hormone deficiency. Outside that diagnostic context, it is used in research settings for body composition, tissue repair, and anti-aging applications.

What does GHRP-2 do?

GHRP-2 stimulates the body's own pituitary gland to produce and release a pulse of growth hormone, which in turn elevates IGF-1 , the primary downstream mediator of GH's anabolic effects. The practical outcomes associated with this GH axis stimulation include support for lean muscle mass, reduction in body fat, accelerated tissue repair and recovery, improved sleep depth, and appetite stimulation. GHRP-2 also moderately elevates cortisol and prolactin alongside GH, which distinguishes it from more selective alternatives.

How long does GHRP-2 take to work?

GHRP-2 produces measurable GH elevation within 15-30 minutes of injection , the acute GH pulse is among the fastest-acting effects of any GHS peptide. Noticeable changes in appetite and sleep quality are commonly reported within the first week or two of use. Body composition changes and recovery benefits typically require 6-16 weeks of consistent use before becoming clearly apparent, with the most meaningful results documented in protocols of 3-6 months.

What is the typical dose of GHRP-2?

Published research and tracked investigational protocols document GHRP-2 use in the range of 100-300 mcg per injection, administered 2-3 times daily. The 100 mcg dose is most commonly used in formal research studies; mid-range doses of 150-200 mcg per injection are frequently reported in investigational body composition and recovery protocols. Optimal dosing for any individual depends on health status, body weight, goals, and other compounds being used , MyPeptidePal builds personalized protocols around those specific variables.

Is GHRP-2 legal?

GHRP-2 is classified as a research compound in most jurisdictions and is not approved for human therapeutic use in the United States, European Union, Canada, or United Kingdom. In Japan, it holds regulatory approval specifically as a diagnostic agent under the name Pralmorelin , not as a therapeutic drug. For competitive athletes, GHRP-2 is explicitly prohibited under WADA category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) both in-competition and out-of-competition. Legal status varies by country and users are responsible for understanding the rules in their location.

Can GHRP-2 be taken orally?

No , oral administration of GHRP-2 produces negligible bioavailability, estimated below 1%. Like virtually all peptides, GHRP-2 is broken down by digestive enzymes in the stomach and small intestine before it can reach systemic circulation in active form. While GHRP-2's D-amino acid modifications do confer some resistance to enzymatic degradation , extending its plasma half-life compared to simpler linear peptides , this resistance is not sufficient to survive the GI tract intact in meaningful quantities. Subcutaneous injection is the standard route for investigational use.

Does the timing of GHRP-2 injection relative to meals actually matter?

Yes , it matters significantly and is one of the most practically important variables in GHRP-2 use. Carbohydrates and dietary fats in the bloodstream following a meal elevate blood glucose and free fatty acids, which suppress the GH response by reducing somatotroph sensitivity. Studies confirm that GHRP-2 administered in a fully fasted state produces meaningfully larger GH pulses than the same dose administered after eating. Standard guidance across tracked investigational protocols is to administer GHRP-2 at least 30-60 minutes before eating or at least two hours after a meal containing carbohydrates or fats.

How does GHRP-2 compare to Ipamorelin, and why would someone choose one over the other?

Both are GHS-R1a agonists that stimulate GH release through the same receptor, but they differ meaningfully in selectivity. GHRP-2 is more potent for GH release but also elevates cortisol and prolactin alongside GH , these hormonal co-effects are dose-dependent but consistent across users. Ipamorelin is designed for high selectivity, producing GH stimulation with minimal cortisol or prolactin response. Users who prioritize a cleaner side effect profile , particularly those concerned about chronic cortisol effects or who are sensitive to prolactin elevation , tend to favor Ipamorelin. Users who want maximum GH amplitude and can tolerate the broader hormonal effects often choose GHRP-2, sometimes combined with a GHRH analog to further amplify the response.

What is the Pralmorelin test, and why does it matter for understanding GHRP-2?

The Pralmorelin stimulation test is a diagnostic procedure used in Japan to assess pituitary function and diagnose growth hormone deficiency. A single intravenous dose of GHRP-2 is administered under clinical supervision, and blood is drawn at defined intervals to measure peak GH output , a peak below a certain threshold indicates inadequate pituitary secretory capacity. Its significance for understanding GHRP-2 is that this diagnostic application represents the only context where the compound has undergone formal regulatory review and received market approval anywhere in the world, making the Japanese clinical literature the highest-quality human evidence available for GHRP-2's GH-stimulating activity.

Does GHRP-2 cause receptor desensitization over time?

This is a legitimate question with a nuanced answer. Theoretical concern about GHS-R1a desensitization with prolonged GHRP-2 use exists, and some evidence from animal models suggests that very high-dose continuous administration can reduce receptor sensitivity over time. However, tracked protocol data does not consistently show clinically significant loss of efficacy at standard doses over the 3-6 month cycles most commonly used , and some studies in aging populations showed maintained GH response over the study duration. The practical guidance from most documented protocols is to consider cycling (for example, 3 months on, 4-6 weeks off) as a precaution, but this is not strongly mandated by the available evidence.

Final Thoughts on GHRP-2 Peptide

GHRP-2 has earned its place as one of the most studied compounds in the GHS peptide class , and the evidence that supports it is more varied than most comparable peptides can claim. It has human clinical data confirming its core mechanism, regulatory approval in one major market for diagnostic use, a substantial preclinical literature covering cardioprotection and body composition, and a real-world protocol track record documented across thousands of active users. The thing it does , pressing the pituitary's GH release mechanism while simultaneously reducing the brake , is well-characterized at both the receptor and physiological level. That foundation matters.

What the evidence does not yet provide is the long-term therapeutic safety picture. The cortisol and prolactin co-stimulation that distinguishes GHRP-2 from more selective options like Ipamorelin is a genuine tradeoff that deserves honest consideration, not dismissal. GHRP-2's classification under WADA's S2 category is not ambiguous , it is specifically listed and prohibited. And the body composition, tissue repair, and anti-aging applications that account for most investigational use are supported by animal data and small, short-duration human studies rather than large controlled trials. Understanding what the evidence actually shows , and where it has gaps , is what informed use looks like.

If GHRP-2's profile fits your goals, the next step is building a protocol that reflects your specific situation rather than a generic starting point. The broad ranges in this guide give you orientation, but the variables that matter most , your health history, body weight, what else you are using, what outcome you are targeting , require a personalized approach. That is exactly what MyPeptidePal is built to do: take the broad science and translate it into a protocol built around you.

References

The editorial team must independently verify and add a minimum of five hyperlinked APA-format citations before this article is cleared for publication. No source URLs with independently confirmed publication details were available at the time of drafting. Key databases and resources to search: PubMed/NCBI (search terms: "Pralmorelin," "GHRP-2," "growth hormone releasing peptide-2," "KP-102"), the WADA Prohibited List at wada-ama.org, FDA enforcement communications regarding peptide compounding, Japanese prescribing information for Pralmorelin via Kaken Pharmaceutical, and Japanese Society of Endocrinology diagnostic guidelines. Every citation added must be independently verified at the source before inclusion. Do not include any citation that cannot be confirmed at its stated URL.